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ABSTRACT
Dissemination of malignant cells from primary tumours to metastatic sites
is a key step in cancer progression. Disseminated tumour cells
preferentially settle in specific target organs, and the success of such
metastases depends on dynamic interactions between cancer cells and
themicroenvironments they encounter at secondary sites. Two emerging
concepts concerning the biology of metastasis are that organ-specific
microenvironments influence the fate of disseminated cancer cells, and
that cancer cell-extracellular matrix interactions have important roles at all
stages of the metastatic cascade. The extracellular matrix is the complex
and dynamic non-cellular component of tissues that provides a physical
scaffold and conveys essential adhesive and paracrine signals for a
tissue’s function. Here, we focus on how extracellular matrix dynamics
contribute to liver metastases – a common and deadly event.We discuss
how matrix components of the healthy and premetastatic liver support
early seeding of disseminated cancer cells, and how the matrix derived
from both cancer and liver contributes to the changes in niche
composition as metastasis progresses. We also highlight the technical
developments that are providing new insights into the stochastic, dynamic
and multifaceted roles of the liver extracellular matrix in permitting and
sustaining metastasis. An understanding of the contribution of the
extracellular matrix to different stages of metastasis may well pave the
way to targeted and effective therapies against metastatic disease.
KEY WORDS: Cancer metastasis, Extracellular matrix, Liver
metastasis, Metastatic niche
Introduction
Metastatic disease is the most common cause of death for most solid
tumour patients, and highly metastatic cancers such as pancreatic
adenocarcinoma (PDAC) and colorectal cancer (CRC) have
particularly poor 5-year survival rates that worsen with metastatic
burden (Dillekås et al., 2019). Although therapies specifically
targeting metastatic disease are still uncommon, our understanding
of how cancer cells escape the primary tumour and establish
themselves in secondary sites has improved significantly over the
past two decades. Metastasis of solid tumours requires intravasation
of tumour cells into blood or lymphatic vessels, survival in
circulation and subsequent extravasation, followed by dormancy
(see Glossary, Box 1) or growth at distant sites.
Disseminated tumour cells (DTCs) preferentially settle in specific
organs driven by factors including tissue mechanical properties
(Reuten et al., 2021), vascular physiology (Follain et al., 2018) and
microenvironment (Ingangi et al., 2019). Conceptualised in Paget’s
‘soil and seed’ hypothesis, there is now ample evidence that
progression of metastases requires favourable local conditions in
different organs that develop to form the ‘metastatic niche’ (Paget,
1889). Our current understanding of this phenomenon is largely
based on the lung metastatic niche and metastatic breast cancer.
These studies have highlighted the importance of niche-specific cell
types and tissue structures in metastatic progression (Montagner
et al., 2020; Altorki et al., 2019). However, the liver is another
metastatic site that warrants study owing to, first, its involvement in
aggressive cancers including pancreatic, colorectal, breast and lung
cancer; second, its association with poor survival compared with
other metastatic sites; and third, the liver’s unique architecture,
vascular physiology and cell composition (Budczies et al., 2015;
Sahin et al., 2018). Understanding how features of the liver
metastatic niche (LMN; Box 1) help support metastases from
tumours of different primary origin is of vital importance in the
development of effective therapies against metastatic disease.
A key component of the metastatic niche is the extracellular matrix
(ECM) – the collection of extracellular proteins that provide the three-
dimensional (3D) scaffold within which cells organise to form
complex structures. Historically, ECM has referred to the families of
fibrillar proteins (collagens), glycoproteins (fibronectin, laminins) and
proteoglycans (heparin sulphate proteoglycans, versican) that form a
dynamic interface for mechanical and biochemical interactions with
cells. This view has recently expanded to include proteins that regulate
ECM secretion, processing, remodelling, degradation and binding –
collectively referred to as the matrisome (Box 1) (Naba et al., 2012).
Indeed, remodelling of the ECM can release growth factors and
signalling molecules trapped within it, linking ECM dynamics to a
plethora of biological consequences for the cells.
DTCs utilise ECM dynamics to create a supportive niche within
which they can survive, evade immune destruction and eventually
proliferate. To date, most studies of the ECM in liver metastasis have
focused either on the most abundant fibrillar ECM components or
on the broader effects of ECMdeposition on tissue mechanics (Shen
et al., 2020), immune penetration (Hu et al., 2019) and metastatic
burden. What is less clear is how ECM dynamics develop as
metastasis progresses and which cell-ECM interactions are
particularly relevant. Studies comparing the cellular origins of
ECM in primary tumours and metastatic niches have revealed
contributions from cancer cells (Tian et al., 2020), fibroblasts
(Costa-Silva et al., 2015) and other non-mesenchymal cells of the
tumour microenvironment (Hoshino et al., 2015). This is supported
by reports of unique ECM profiles of liver metastases from tumours
of different origins (Yuzhalin et al., 2019; Hebert et al., 2020; Tian
et al., 2019). Indeed, despite sharing clonal origins within primary
tumours, protein abundance signatures from liver metastases are
unique and favour cellular programmes involved in ECM-receptor
interactions and cell adhesion (Li et al., 2020).
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We propose that several key questions need to be addressed to
better understand the liver metastatic niche. (1)What is the functional
relevance of cell type-specific matrisome secretion? (2) How does the
ECM compartment of the LMN develop during metastatic
progression? (3) Do any cell-ECM interactions represent
bottlenecks or decision points in the metastatic fate? Tackling these
questions will advance our understanding of the roles of the ECM in
the metastatic process and hopefully identify novel therapeutic targets
for anti-metastatic treatments.
This Review focuses on how ECMdynamics in the liver metastatic
niche emerge and how these changes determine metastatic fate. Of
note, we do not aim to cover the extensive literature showing the
general impact of matrix stiffness, integrin-adhesion complexes and
specific ECM-cell interactions on various aspects of cancer cell
biology, which have been extensively reviewed elsewhere (Leight
et al., 2017; Nallanthighal et al., 2019; Zanconato et al., 2019;
Papalazarou et al., 2018). Instead, we highlight the different models
and technical approaches used to study these processes, and hope that
this discussion provides a basis for a niche-centric perspective on
ECM dynamics during metastasis.
Systems for studying metastatic ECM
A number of different model systems are now available to
researchers interested in ECM dynamics and liver metastasis
(Table 1). These fall on a spectrum that balances physiological
relevance with ease of use and adaptability. Until recently, the
workhorse of cancer biology research has arguably been 2D cell
cultures derived from tumours, which, although useful for studying
fundamental cancer cell biology, do not accurately recapitulate cell-
ECM interactions in tumours.
Three-dimensional cell cultures can better model the physical
properties of tissues and the heterogeneity of the cells and ECM
within them. Organoids (Box 1) partially re-create the microstructure
of organs, including the liver (Hu et al., 2019). Their cellularity is
limited by the potency of the stem cell population and usually they
require embedding in an exogenous ECM substrate, e.g. the
commercially available Matrigel. Spheroids (Box 1) can contain
several predefined cell types at the expense of a developmentally
programmed microstructure (Lucendo-Villarin et al., 2019). The
inclusion of immune cells in both organoid (Neal et al., 2018) and
spheroid (Yin et al., 2016) systems can further recapitulate the tumour
microenvironment. Both malignant organoids and spheroids secrete
more ECM than 2D cultures and form microenvironments with
similarities to their in vivo counterparts (Longati et al., 2013).
Microphysiological systems (MPSs; Box 1), also known as
organ-on-a-chip, rely on advances in 3D printing and small-scale
bioengineering to further model tissue architecture and multi-organ
systems. In particular, MPSs excel at modelling structural tissue
properties such as blood flow and nutrient gradients, which have
been shown to regulate DTC-endothelial cell interactions during
extravasation (Follain et al., 2018; Ando et al., 2017). Although
significant efforts have been made to develop liver-on-a-chip
models (Jang et al., 2019; Gori et al., 2016), to date there are few
examples of their applications in metastasis research.
Despite these advances, tissue-based systems remain the gold
standard for studying the composition and structure of metastatic
ECM. Patient biopsies (Naba et al., 2014), genetically engineered
mouse models (GEMMs; Box 1) (Wishart et al., 2020) and cancer
cell transplant models (Box 1) (Hebert et al., 2020) all generate
metastatic tissue samples that can be used to characterise ECM state.
An important recent advance is decellularisation – removing cells
from these tissues without compromising the extracellular
compartment. Decellularised tissues enable quantitative profiling
of the matrisome (Naba et al., 2017) and multiplexed imaging of the
3D organisation of the ECM (Mayorca-Guiliani et al., 2019), and
can be used as a 3D culture scaffold to reintroduce cells into
(Wishart et al., 2020). Although they are informative, there are
limitations to their use. Current proteomic applications are limited
by the need for gross changes in ECM to detect differences
Box 1. Glossary
Basement membrane (BM): the extracellular matrix (ECM) structure
produced by epithelial cells, endothelial cells, adipocytes and other cell
types, which provides structure to a tissue and maintains the polarity and
identity of adjacent cells.
Dormancy: a net non-proliferative state in which cancer cells can survive
immune clearance and chemotherapies, and can reawaken to initiate
metastases in response to external cues.
Epithelial-to-mesenchymal transition (EMT): also referred to as
epithelial-to-mesenchymal plasticity. The transition of cells between
epithelial and mesenchymal cell states in which cells lose their polarity
and gain an increased invasive capacity. This transition defines broad
transcriptional profiles and changes in cell-cell contacts, migration and
proliferation. The same cellular processes are also involved in the
reverse, mesenchymal-to-epithelial transition.
Genetically engineeredmousemodels (GEMMs):mousemodels with
genetic lesions that predispose them to tumourigenesis. Genetic lesions
can be either be global (e.g. Tp53 knockout) or targeted to a particular
tissue or cell type (e.g. Pdx1-Cre in the KPC mouse model of pancreatic
cancer).
Hepatic stellate cell (HSC): a mesenchymal cell type occupying the
space of Disse in the liver sinusoids. During inflammation, fibrosis or
metastasis, these cells can transdifferentiate to activatedmyofibroblasts,
leading to bulk secretion of extracellular matrix.
Hepatocyte: the major parenchymal cell type of the liver that performs
the majority of metabolic functions.
Interstitial ECM: ECM structures that support the bulk tissue of organs.
This matrix is primarily produced by the parenchymal cells, i.e.
hepatocytes in the liver.
Kupffer cell: liver-resident macrophage lining the sinusoidal vessels.
Liver metastatic niche (LMN): the combined cellular and acellular
microenvironment occupied by tumour cells that have disseminated to
the liver. The niche is not static, but changes in response to cues from
cancer cells and external factors (e.g. infiltrating immune cells).
Matrisome: the collection of >1000 genes that produce the ECM
components or the proteins that directly interact with them. The
matrisome was collated through proteomic analyses of decellularised
tissues.
Microphysiological system (MPS): in vitro models that aim to
recapitulate the key features of in vivo tissues, including 3D
architecture, cellular composition and blood flow.
Organoids and spheroids: self-organised 3D cell cultures generated
from stem cells or primary tumour cells. Organoids typically contain
multiple cell types and recapitulate the tissue architecture of an organ,
whereas spheroids are cellular aggregates typically composed of a
single type of differentiated but immortalised cells, such as cancer cells
or cell lines.
Sinusoid: sinusoids are low-pressure fenestrated capillaries in the liver
that link the hepatic artery and portal vein at the periphery of lobules to
deliver blood into central veins. Sinusoids are lined with endothelial cells
and flanked by hepatocytes.
Space of Disse: area between the sinusoid and hepatocytes in the liver.
In healthy liver, the space is occupied by hepatic stellate cells and
microvilli from hepatocytes.
Transplant model:models in which malignant cell lines or primary cells
are transplanted into animals, most often mice. Orthotopic models
generate primary tumours, whereas injecting cells into the circulation,
e.g. into the tail vein or spleen, provides rapid-onset metastases in
specific target organs.
2



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































compared to control tissues, precluding their use for characterising
localised changes, such as those that might occur early in metastasis.
Decellularised tissues also represent a static snapshot of the ECM
state and are of limited use in assessing ECM dynamics. Finally,
retention of ECM proteins is protocol and tissue dependent (Krasny
et al., 2016), which can affect experimental results.
The stochastic nature of metastasis has made tracking its
progression within tissue samples challenging. Thus, the majority
of research has relied on bulk metastatic burden as a primary
endpoint. Although this research has been informative, it has led to a
relatively poor understanding of the early events within the
metastatic niche. Functional insight into genes associated with
liver metastasis has also been limited and has mainly relied on
analyses of tissue transcriptomics and patient survival. How the
different models described here have begun to expand our
knowledge of the metastatic cascade is discussed below.
Profiling the liver matrisome during metastasis
Healthy liver structure and ECM
The liver is the largest internal organ in the body and the major site
of drug metabolism, blood detoxification, glucose storage and bile
production (Stanger, 2015). These functions are facilitated by a
hierarchical, 3D structure of liver lobes, lobules and lobule
substructures (Fig. 1). Blood enters the organ via two vessels: the
hepatic artery, which delivers fresh blood, and the portal vein, which
delivers blood from the gastrointestinal system, gallbladder,
pancreas and spleen. These major vascular systems converge in a
network of sinusoids (Box 1). Sinusoids have a polar arrangement,
with the portal triad (hepatic artery, portal vein, bile duct) at one end
and a central vein at the other, which takes blood away from the
liver. Hepatocytes (Box 1) are the major epithelial parenchymal cell
in the liver, constituting ∼60% of all cells, and fill the space in-
between the sinusoids. Another epithelial cell population called
cholangiocytes line the bile duct. Additionally, the liver contains
various non-parenchymal cells that support parenchymal cell
function, including liver sinusoidal endothelial cells (LSECs), a
resident macrophage population called Kupffer cells (Box 1) and
hepatic stellate cells (HSCs; Box 1), a type of mesenchymal
fibroblast-like cell, which occupy the space of Disse (Box 1). An
important consequence of liver lobule polarisation is the hypoxic
gradient that exists from the highly oxygenated cells near the portal
triad to the mildly hypoxic ones near the central vein (Fig. 1). This
zonation has well-established consequences for the metabolic
functions of hepatocytes; periportal hepatocytes conduct oxygen-
intensive functions such as glycogen metabolic and amino acid
utilisation, whereas pericentral hepatocytes perform glycolysis and
glutamine synthesis (Jungermann and Katz, 1989). Recently, the
position along the portocentral axis has been shown to also affect
gene expression in LSECs (Aizarani et al., 2019) and HSCs (Dobie
et al., 2019). Whether this heterogeneity influences interactions
with DTCs is currently unknown.
The healthy liver is thought to have a relatively minimal ECM
component. The sinusoidal endothelium lacks a typical complete
basement membrane (BM; Box 1) to facilitate material exchange,
although the key fibrillar ECM proteins such as laminin, collagen
IV and fibronectin line the sinusoids (Pozzi et al., 2017; Rosenow
et al., 2008). Recent proteomic studies of the heathy liver matrisome
have revealed a more diverse set of core matrisome components
including collagens, fibulins, annexins and elastins (Goddard et al.,
2016; Krasny et al., 2016; Naba et al., 2014). Collagens I, IV and VI
are particularly abundant, with collagens IV and VI forming part of
the liver’s BM structures, whereas collagen I is found more
predominantly in the interstitial ECM (Box 1). The organisation of
interstitial collagens has recently been imaged in 3D using
decellularised liver preparations (Mayorca-Guiliani et al., 2019),
revealing that collagens I, VII and XIV have unique patterns
characterised by different levels of fibre bundling and alignment that
determine their effects on tissue mechanics. It is worth noting that
these ECM factors are secreted by hepatocytes and cholangiocytes,
not HSCs, in the healthy liver. Single-cell RNA sequencing
(RNAseq) of murine HSCs has, however, identified a number of
matrisome components differentially expressed along the
centroportal axis; Podn, Loxl1 and Adamtsl2 show pericentral
expression, whereas Igfbp3 and Itgb3 are periportal (Dobie et al.,
2019). The functional relevance of these asymmetries is currently
unknown, but warrants further study.
Liver fibrosis is one of the most extensively studied examples of
aberrant ECM accumulation, and has been suggested as a model for
understanding ECM changes in liver metastasis (Lee et al., 2019;
Zhao et al., 2017). A detailed discussion of ECM changes in liver
fibrosis is beyond the scope of this Review and has been excellently
described recently (Arteel and Naba, 2020). However, several
developments in the field have direct relevance to the study of
metastatic ECMchanges in the liver. First, proteomic analyses of liver
tissue at different stages of fibrosis has shown that different ECM
proteins are enriched at specific times in the fibrotic cascade
(Baiocchini et al., 2016). Second, although HSCs are the major
depositors of ECM during liver fibrosis, recent studies have identified
spatially distinct subpopulations of HSCs that respond to chemically
induced fibrosis (Mederacke et al., 2013; Dobie et al., 2019). The
activation of HSCs is partly driven by inflammatory signals from
resident and invading immune cells (Tsuchida and Friedman, 2017).
Finally, there is extensive evidence for reversal of severe liver fibrosis
in humans and preclinical models (Iredale et al., 1998; Schiff et al.,
2011). The signalling pathways underlying such reversal could have
particular relevance in targeting ECM deposition during metastasis.
Reversal of fibrosis also points to the adaptability and dynamism of
the liver ECM, even in disease states. Combined, these studies
highlight the importance of understanding spatial and temporal
aspects of ECM dynamics in the liver.
The liver premetastatic niche
The concept that cancers can influence the biology of distant organs
through their shared circulation even before cells disseminate from
the primary tumour is an emerging and sometimes controversial
area of study. Communication from the primary tumour has been
proposed to create a more favourable environment for metastatic
seeding, known as the premetastatic niche (PMN). The signals that
generate PMNs have organ-specific features, but converge on
common events such as infiltration of bone marrow-derived and
immune cells, and ECM changes (Peinado et al., 2017).
As PMN formation requires both an intact immune system and a
primary tumour, genetically engineered mice and orthotopic
injection models have been critical to researching this
phenomenon. The KPC mouse is a pancreatic cancer model in
which targeted mutations in Tp53 (also known as Trp53) and Kras
lead to PDAC and liver metastases (Hingorani et al., 2005). This
model was used recently to show that livers of tumour-bearing mice
have enhanced fibronectin and collagen I deposition prior to overt
metastases (Lee et al., 2019). RNAseq of these livers found altered
expression of transcripts encoding other matrisome components,
including matrix metalloproteinase 9 (Mmp9) and S100a proteins
(Lee et al., 2019), which were previously co-associated with
metastasis at other sites (Lloyd et al., 1998; Zhang et al., 2011).
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These changes depend on an interleukin-6 (IL-6)/phospho-STAT3/
serum amyloid A (SAA) signalling cascade in hepatocytes (Lee
et al., 2019), which has also been implicated in CRC liver
metastases (Lin et al., 2019). Interestingly, this signalling pathway
has well-established roles in liver regeneration (Klein et al., 2005)
and innate immunity (Zhou et al., 2016). Indeed, although the origin
of premetastatic ECM deposition is currently unclear, IL-6 and SAA
proteins are both involved in HSC-mediated fibrosis during the
acute-phase response, which is the early inflammatory response to
injury or infection (Siegmund et al., 2016; Xiang et al., 2018). Thus,
signals from the primary tumour appear to hijack innate immune
and homeostatic pathways in hepatocytes to drive ECM changes
prior to the arrival of DTCs.
Another emerging concept is that fibronectin deposition in the
liver PMN could be caused by signalling from extracellular vesicles
(EVs) secreted by the primary tumour. Pre-treating mice with
PDAC-derived EVs enhanced subsequent seeding of PDAC DTCs
in the liver in an intrasplenic injection model (Costa-Silva et al.,
2015). The authors showed that EV-derived macrophage migration
inhibitory factor is taken up by Kupffer cells to initiate a fibrotic
cascade driven by transforming growth factor β (TGF-β) signalling
to HSCs. Indeed, the abundance of integrin αvβ5 in EVs directs
uptake in the liver over lung or brain through its interaction
with Kupffer cells (Hoshino et al., 2015). Additionally, EVs in
the duct fluid of PDAC patients have also been shown to contain
ECM components, including tenascin-C, MMP7 and laminins,
pointing to a direct contribution to ECM from primary tumours
(Zheng et al., 2018).
ECM changes in the liver PMN appear to be critical for immune cell
recruitment. Increased fibronectin deposition promotes macrophage
infiltration into the liver, a precursor step to PMN formation (Costa-
Silva et al., 2015). Additionally, the metalloprotease inhibitor TIMP1,
released by primary CRC tumours, induces neutrophil recruitment via
a stromal cell-derived factor 1/C-X-C chemokine receptor 4 signalling
axis in the liver prior to cancer cell arrival (Grünwald et al., 2016;


































Cholangiocyte HSC Kuppfer cell LSEC
Hepatic
artery
Fig. 1. Liver structure, and cellular and common ECM proteins. Liver tissue is organised into discrete functional units called lobules that have a hexagonal
arrangement of portal triads around a central vein, linked by sinusoids. LSECs line the sinusoid, whereas HSCs occupy the space of Disse that separates the
sinusoid from hepatocytes. The different microstructures within the sinusoid have unique ECM compositions, shown in the boxes. A partial basement
membrane lines the space of Disse, facilitating exchange of nutrients, proteins and xenobiotics. The interstitial matrix includes typical ECM components such as
fibronectin and collagen I that support tissue structure and integrity. Differences also exist in ECM composition along the centroportal axis, although the functional
relevance of this is unclear. CSPG, chondroitin sulfate proteoglycan 4; DSPG, dermatan sulfate proteoglycan; ECM, extracellular matrix; HSC, hepatic
stellate cell; HSPG2, heparan sulfate proteoglycan core protein 2; LSEC, liver sinusoid endothelial cell; NGFR, tumour necrosis factor receptor superfamily
member 16; TGFB1, transforming growth factor beta 1. The sinusoid and lobule structures are adapted from Frevert et al. (2005) and theWikipedia Commons file
201904_hepatic_lobule.svg under the terms of the CC-BY 2.5 and 4.0 license, respectively.
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transformation of HSCs, macrophages and neutrophils also secrete a
unique combination of matrisome proteins that facilitate migration via
ECM degradation (Etich et al., 2019; Nielsen et al., 2016). The
relevance of direct ECM deposition by immune cells is currently
unclear, but could significantly contribute to local ECM remodelling
given the abundance of these cells in the PMN.
Thus, altered ECM is a canonical feature of the liver PMN that is
required for its pro-metastatic effects. Our understanding of these
changes remains very rudimentary, and a comprehensive
assessment of the matrisome signature of the liver PMN is still
lacking. In humans, liver metastases can often occur on a backdrop
of liver disease-mediated fibrosis. Whether this causally promotes
metastasis remains unresolved, but understanding the relationship
between fibrosis in liver disease versus pre-metastatic livers is a
fruitful avenue for future research (Kondo et al., 2016).
The metastatic liver ECM
Metastatic disease dramatically alters the cellular and extracellular
composition of the liver. Indeed, unbiased transcriptomics and
proteomics of human CRC liver metastases and primary tumours
have identified ECM and cell adhesion programmes as the key
differentially expressed pathways (Lin et al., 2011; Del Rio et al.,
2013; Li et al., 2020).
These changes have recently been elucidated in spectacular detail
through advances in decellularisation techniques, enabling
proteomic analyses of the decellularised ECM (dECM) of healthy
and metastatic livers. One such study using CRC patient tissue
identified 56 matrisome proteins that were upregulated in metastatic
livers, several of which were not expressed in either primary tumour
or normal liver samples (Naba et al., 2014). These included both
core matrisome (Comp, Fndc1, Igfals, Spp1) and matrisome-
associated (Bmp1, C1qtnf5, Hpx) proteins, and suggest that unique
ECM profiles can arise from the interactions between DTCs and the
liver stroma. A similar study using intrasplenic injection of the CRC
cell line MC38 identified a 13-protein ECM signature of liver
metastases that included S100a proteins 4, 6 and 11, annexins 1 and
2, and a number of glycoproteins, such as Thbs3, Sparc, Emilin2
and Fbln2 (Yuzhalin et al., 2019).
DTCs of different origins produce unique matrisome signatures
distinct from other cancer types and from the normal liver stroma.
Orthotopic or injection models of human cancer cell lines into severe
combined immunodeficient (SCID) or nude mice allows the
separation of matrisome signatures from the host stromal ECM
through identification of species-specific peptides. This approach was
recently used to show that the liver, lung, brain and bone metastases
disseminated upon injection of the human breast cancer cell line
MDA-MB-231 had markedly different ECM signatures compared to
both the original cancer cells and the host stroma (Hebert et al., 2020).
This elegantly shows the importance of the metastatic niche in
influencing the ECM identity of cancer cells. The liver metastasis-
specific ECM signature included cancer cell-derived collagen VI and
stroma-derived tenascin-C, collagen VI and collagen XIV, fibronectin
and fibrinogens. Interestingly, collagen VI is one of the more abundant
ECM components of normal liver and has been associated with
metastasis in breast cancer (Wishart et al., 2020) and PDAC (Owusu-
Ansah et al., 2019) but the functional relevance of these liver-specific
ECM components remains unclear. However, knockdown of the brain
metastasis-enriched SERPINB1 specifically reduced brain metastases
(Hebert et al., 2020), implying that these unique signatures do have
functional relevance.
Growth patterns of liver metastases also differ greatly depending
on their origin. Liver metastases from breast cancers typically adopt a
‘replacement’ strategy whereby cancer cells take over the space
occupied by hepatocytes and co-opt the existing sinusoid vasculature
(Stessels et al., 2004). In contrast, CRC liver metastases are more
disruptive of the overall liver architecture, with a subset of these CRC
metastases developing distinct ‘desmoplasmic’ accumulations of
ECM between the invasive front and the liver stroma, which is also
seen in PDAC liver metastases (Vermeulen et al., 2001; Whatcott
et al., 2015). Although these histopathological subtypes have
distinct ECM distributions, a systematic comparison of matrisome
compositions is lacking and may shed light on why different growth
patterns have differential prognoses (Fernández Moro et al., 2018).
Progression in space and time
Although they are immensely informative, proteomic studies of
metastasis-associated ECM have limitations and could benefit from
new technical developments. Importantly, the existing approaches
do not retain spatial and temporal information – the when and where
of ECM dynamics. As shown for primary tumour progression and
liver fibrosis, matrisome signatures develop as the cellular
composition and relevant signalling pathways change (Baiocchini
et al., 2016; Tian et al., 2019). There are technical limitations in
isolating smaller early metastases, which are otherwise outweighed
by the bulk of normal liver tissue in dECM preparations. Techniques
such as laser capture microdissection in combination with mass
spectrometry have been used to isolate and profile micrometastases
and ECM, and could be useful (Herrera et al., 2020; Elbouchtaoui
et al., 2018). This technique can also be used to profile different
parts of the tumour, such as the invasive front, to include spatial
information (Carnielli et al., 2018).
Multiplexed imaging-based techniques provide an alternative
approach. Aiello et al. (2016) used a fluorescent reporter KPC
mouse line to characterise the cellular and molecular composition of
spontaneous liver metastases of different sizes. They showed that
the density of myofibroblasts in metastases increased linearly with
metastasis size, and that this correlated with levels of collagen I
and the glycoprotein osteonectin. Interestingly, fibronectin and
hyaluronic acid density peaked in micro- or milli-sized metastases,
challenging the assumptions of runaway fibrosis, even in
desmoplasmic metastases such as those of PDAC.
Although definitive studies of the human liver metastasis
microenvironment are lacking and would provide a very important
perspective on this issue, these existing studies have begun to shed
light on early ECM dynamics in the metastatic liver and cellular
composition. A holistic understanding of this process will require
integration of quantitative ‘omics’ approaches with spatial
information across the chronology of metastasis. Additional
considerations for matrix proteins studies include how ECM
components integrate into tissue architecture and which cells they
associate with.
ECM dynamics in the metastatic cascade
The previous section summarised the known changes of the liver
ECM asmetastasis progresses, and how some of these changes drive
recruitment of different cellular components of the metastatic
microenvironment. Here, we outline the current understanding of
how these cell-ECM interactions influence the fate of liver
metastases.
Circulating tumour cells and extravasation
To enter the bloodstream, cancer cells must migrate out of the
primary tumour site and into the vasculature (intravasation) or at
least be able to enter the leaky tumour vasculature. Although this is a
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critical step in haematogenous metastasis and involves interactions
between cancer cells and the BM, it is not thought to be specific to
liver tropism and has been reviewed elsewhere (Chiang et al., 2016;
Kai et al., 2019). DTCs residing in the blood or lymph are referred to
as circulating tumour cells (CTCs), and face a hostile and novel
environment to survive in prior to reaching the liver (Blomberg
et al., 2018). Indeed, it is estimated that less than 0.02% of DTCs
seed metastases, with the rest cleared from circulation either by
immune capture, oxidative damage or anoikis, a programmed death
due to lack of cell adhesion (Celià-Terrassa and Kang, 2016).
Interestingly, there is emerging evidence that cancer cells with
high levels of ECM production can more effectively combat these
barriers, as has been shown in vitro for drug resistance (Işeri et al.,
2010). Single-cell RNAseq of CTCs from pancreatic, breast and
prostate cancer patients has shown an increase in expression of core
matrisome components, including SPARC, MGP and SPON2, that
correlated with a shift towards a mesenchymal cell state (Ting et al.,
2014). One potential cell survival benefit of enhanced ECM
secretion is that it promotes clustering of CTCs with each other and
with blood cells to escape anoikis. Indeed, CTC and CTC-platelet
clusters have enhanced survival in circulation, and are supported by
CTC-derived collagen I (Aceto et al., 2014; Xiong et al., 2020).
Clustering can also be supported by cancer-associated fibroblasts
through inducing the production of pro-clustering proteins such as
the CEACAM proteins (Matsumura et al., 2019). CTC clusters have
been isolated from patients and cultured in vitro in low-adhesive
conditions, although the matrisome signatures from these cultures
were not reported (Yu et al., 2014; Cayrefourcq et al., 2015).
Once in the liver vasculature, CTC-derived ECM proteins
support extravasation into sinusoids. A recent study investigated
the function of two candidate cancer cell-derived matrisome genes,
SERPINB5 and CSTB, that were highly expressed in PDAC and
associated with poor survival (Tian et al., 2020). Orthotopic
injection of a human breast cancer cell line modified for stable
knockdown of SERPINB5 andCSTB showed that these two proteins
promote liver metastasis owing to enhanced invadopodia formation
supporting extravasation. Binding of CTCs to the fibronectin- and
collagen IV-rich sinusoid ECM is also a critical requirement for
extravasation. In breast cancer liver metastasis, claudin-2 is
overexpressed specifically in the liver and enhances binding to
sinusoidal ECM through upregulation of α2β1 and α5β1 integrin
complexes (Tabaries̀ et al., 2011). Indeed, integrin-mediated
binding of DTCs to sinusoidal ECM is important for successful
formation of liver metastases (Enns et al., 2004). Thus, both DTC-
and liver sinusoid cell-secreted ECM proteins are important in
seeding of liver metastases. Whether increased ECM secretion by
DTCs is driven by selection or specific intracellular pathways, e.g.
mechanosensitive transcription networks, is as yet unclear.
EMT, growth and migration
Once DTCs arrive in the liver, interactions with the surrounding
microenvironment support survival and proliferation. Epithelial-to-
mesenchymal transition (EMT; Box 1) describes an orchestrated cell
state change that occurs during normal tissue development but can be
reinitiated in certain pathological conditions, particularly cancer.
Indeed, plasticity along the EMT axis has emerged as a master
regulator of many core features of cancer cell behaviour, migration,
proliferation and immune escape as metastatic nodules develop
(Bakir et al., 2020). Transcriptional changes associated with EMT can
be driven by a number of different mechanisms, including
transcription factor activation, epigenetic reprogramming and
altered proteasome activity. Cell-ECM signalling is a crucial
upstream component of these pathways. Stiff environments induce
nuclear translocation of YAP/TAZ to activate canonical EMT
transcription factors (Zanconato et al., 2019), and promoter
methylation of genes that control cell identity, such as Sox2 (Tan
et al., 2014).
Engagement of specific ECM ligand-receptor pathways also
promotes EMT in cancer cells. In particular, ECM-integrin pairs
such as fibronectin-αVβ3 (Knowles et al., 2013) and tenascin-C-
αVβ1/6 (Katoh et al., 2013) drive EMT in breast cancer cell lines.
Whether these interactions support EMTof DTCs in liver metastasis
has not been clearly elucidated, although fibronectin and tenascin-C
are upregulated in metastatic livers (see Table 2). Other ECM
proteins enriched in metastatic liver, such as thrombospondin 1,
promote EMT in cancer cells to drive migration and invasion,
although here the importance of integrin binding is unknown (Liu
et al., 2020). Thus, the composition and physical properties of the
ECM have a profound impact on cancer cell identity. Whether EMT
and invasive behaviour promotes liver metastatic potential
generally, or has particular roles in disease progression, requires
further study.
Preparations of dECM from liver metastases provide a valuable tool
to study the direct effects of both physical and ligand-receptor
signalling properties of the matrix on cancer cell behaviour. The
structure and composition of matrix is highly organ specific, as
recently highlighted through dECM analyses of liver and lung tissue
(Tian et al., 2018). Seeding CRC cells onto these scaffolds formed
metastases that are histopathologically and transcriptionally similar to
the in vivo CRC metastases that form in these organs. Interestingly,
CRC cells cultured on liver ECM scaffolds show a greater propensity
to form liver metastases when transplanted in vivo, suggesting that the
liver matrix either selects or influences liver-tropic cancer cells.
D’Angelo et al. (2020) used patient-matched dECM scaffolds from
metastatic or healthy liver tissue combined with a CRC cell line to
show that the metastatic dECM increased migration andmesenchymal
identity of cancer cells compared to the healthy tissue.
A recent study of ECM proteomics from CRC liver metastases
showed dramatically increased citrullination of core matrisome
proteins, including collagens I, II, III, IV and VI, alongside
fibronectin and fibrinogens (Yuzhalin et al., 2018). This enhanced
citrullination was due to secretion of the enzyme PAD4 by CRC cells.
Interestingly, citrullination of collagen I promotes adhesion and
induces epithelial marker expression in CRC cells, suggesting that
modifications of ECM proteins play a role in mesenchymal-to-
epithelial transition – shown to be important for establishing
metastases in the liver (Aiello et al., 2016) and lung (Del Pozo
Martin et al., 2015). This illustrates how the metastatic ECM emerges
from the interplay between ECM secretion and subsequent
modification by both stromal and cancer cells to alter the behaviour
of these cell populations.
Although they are useful for identifying cell-ECM effects, dECM
preparations lose the interactions between stromal and cancer cells
that influence ECM binding, and may release more loosely bound
matrisome components. In mitigating the shortcomings of dECM
systems, 3D cell culture models have been extremely informative.
Gaggioli et al. (2007) grew cancer cell monolayers on a commercial
ECM preparation (Matrigel), collagen I and fibroblasts. The
fibroblasts led collective invasion of the cancer cells along self-
generated tracks of fibrillar collagen and fibronectin (Gaggioli et al.,
2007), and have been shown elsewhere to distort the existing BM to
facilitate cancer cell migration (Glentis et al., 2017). Indeed, the
coupling of activated fibroblasts and cancer cells supports
metastatic seeding in the liver and can be therapeutically targeted
7






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































via inhibition of prolyl hydroxylase domain-containing proteins
(Madsen et al., 2015). Spheroid invasion assays are a popular 3D
culture setup that enable live imaging of a spheroid containing one
or more cell types as they invade into a surrounding matrix-
containing substrate. These have been used to live image fibroblast-
cancer cell interactions and unpick the specific roles of ECM (Attieh
et al., 2017; Miyazaki et al., 2019). One such study showed that
αVβ3 integrin binding to fibronectin, rather than the degradation or
contractile functions of cancer-associated fibroblasts, was critical to
support cancer cell invasion (Attieh et al., 2017). Activated HSCs in
the space of Disse may well support invasion of DTCs from the
inner sinusoids and into the liver parenchyma in a similar manner.
Cancer cell metabolism
As well as plasticity of cell identity, cancer cells must also
reprogramme their metabolism to adapt to novel sources of energy
and provide sufficient ATP production to sustain growth and
invasion. Metabolic profiling of metastases formed by the murine
breast cancer cell line 4T1 showed that cancer cells forming liver
metastases in mice downregulated oxidative phosphorylation
programmes in favour of glycolysis, whereas the opposite was
true for those forming metastases in the lung (Dupuy et al., 2015).
Cancer cells in the liver utilise abundant extracellular creatine to
fuel metastasis (Loo et al., 2015). Interestingly, levels of creatine
kinase B in PDAC cells were recently shown to be upregulated in
stiff environments and important for the establishment of liver
metastases (Papalazarou et al., 2020). This points to an interplay
between the increasingly stiff and fibrotic properties of the liver
metastatic niche and the metabolic strategies adopted by metastatic
cancer cells that seed in the liver. Indeed, many studies have
indicated a selection bias for cells adapted for low-oxygen states in
the liver, conditions generated by dense ECM and associated with
ECM production (Gilkes et al., 2014; Schild et al., 2018).
As well as influencing metabolic state, there is some evidence
that ECM proteins can be used by cancer cells as an independent
source of energy and nutrients. The amino acid proline is both
enriched in many fibrillar ECM proteins and can be a limiting factor
in protein translation in cancer cells (D’Aniello et al., 2020). Cancer
cells can thus use this exogenous source of proline through ECM
degradation and proline uptake pathways, and disrupting this
pathway impairs metastasis in breast cancer models (Elia et al.,
2017). The links between ECM dynamics and cancer cell
metabolism in liver metastases are still poorly understood but
remain a fascinating avenue of research and therapeutics.
Dormancy
DTCs that arrive at metastatic sites can lie dormant for many years in
humans before re-emerging (Riggio et al., 2021). These cells are
often non-cycling and therefore evade many traditional strategies
for targeting tumours, like cytostatic chemotherapy, although there
is also evidence for a key role for the microenvironment in fostering
the protected nature of dormant DTCs (Ingangi et al., 2019). The
dispersed and extremely rare nature of these cells in vivomeans that
progress into understanding dormancy and its niche-specific
requirements is particularly challenging.
In the past decade, ex vivo microphysiological systems (MPSs)
have begun to be used to model the 3D environment, matrix and
cellular composition, and flow of nutrients/gases of the metastatic
niche. Clark et al. (2014) have made considerable steps towards
developing an ex vivo MPS of the liver (LiverChip) using primary
human hepatocytes and non-parenchymal liver cells as a basis
to study hepatic metastatic dormancy. When the highly aggressive
breast cancer cell line MDA-MB-231 is introduced into the liver
MPS, treatment with the chemotherapeutic agent doxycycline
eliminates the majority of cancer cells, leaving a subpopulation of
dormant cells. An update to liver MPS introduced a softer, hydrogel-
based tissue interface containing canonical fibronectin-binding
motifs (Clark et al., 2017) that markedly increased the proportion
of dormant cells. This highlights the importance of both mechanical
and biochemical cues of the ECM to cancer cell quiescence.
Currently, there are major barriers to wider application of these
systems. These include the limited ability to combine MPS models
with functional end points such as transcriptomics, proteomics and
live imaging. Adapting the structural and compositional complexity
of extracellular environments of in vivo ECM into MPSs is another
challenge. Technologies based on decellularised tissue preparations
have begun to close this gap (Ferreira et al., 2020), and simpler,
more controlled environments still provide value in addressing
specific biological questions.
The role of the ECM in liver metastatic dormancy is still largely
unclear. Established in vivo models for cancer cell dormancy in the
lung suggest that reduced matrix stiffness can promote dormancy,
whereas activation of myofibroblasts and increased rigidity promotes
emergence (Barkan et al., 2010). Supporting this, HSCs can induce
dormancy of PDAC DTCs in the mouse liver via IL-8 signalling,
which can be reversed by the transdifferentiation of these HSCs into
myofibroblasts (Lenk et al., 2018). Ma et al. used an intrasplenic
prostate cancer cell injection model to show that hepatocytes drive
mesenchymal-to-epithelial transition in cancer cells, characterised by
increased E-cadherin and ERK and by reduced p38, which leads to
resistance to chemotherapy and increased liver metastasis (Ma et al.,
2016; Ma and Wells, 2014). Analyses of lung metastases have
identified roles for fibronectin and collagen I in inducing and
awakening dormant cancer cells, which will be important to
investigate in the liver (Kai et al., 2019; Barney et al., 2020; Barkan
et al., 2010). Taken together, the role of the ECM in dormancy looks
set to be a field in which technological advances could play a crucial
role in addressing outstanding clinical questions of therapy resistance
and disease recurrence.
Conclusions and future directions
Our understanding of the importance of ECM dynamics in liver
metastasis is entering an exciting phase. The topic lies at the
intersection between two fields – molecular mechanisms of
metastasis and ECM dynamics – that, over the past two decades,
have benefited from technical innovations that have dramatically
changed the way we think about these processes.
Referring back to the questions we initially posed on the cellular
origin, chronology and molecular functions of ECM dynamics in
liver metastases, it is clear that significant advances have been made.
Proteomic studies over the past few years have helped move our
understanding beyond fibrillar-accumulationmodels and illustrate the
plethora of ECM changes that occur at metastatic sites. The use of
xenograft models has revealed important contributions of cancer cell-
derived ECM, although similar distinctions for different stromal cell
populations in the liver are still lacking. Finally, how the ECM
microenvironment changes during the early stages ofmetastasis is not
something addressable by current ‘whole-organ’ techniques for ECM
proteomics, but would be immensely informative in understanding
how pathology progresses.
An emerging question is how best to integrate these ‘omic’
resources with a functional understanding of metastasis. Targeted
studies of ECM proteins have illustrated the diverse mechanisms by
which matrisome proteins influence metastatic cancer cells and the
9


















stroma. Looking forward, in vitro systems such as organoids and
MPSs that are amenable to high-throughput functionally relevant
assays can help identify the ECM proteins important to specific
stages of the metastatic cascade, as they have done for drug sensitivity
studies (Broutier et al., 2017). Additionally, functional insight
from ‘omic’ studies, such as predicting cell-cell interactions from
RNAseq data, could help identify key cell-ECM interactions
within complex microenvironments in vivo (Efremova et al., 2020;
Browaeys et al., 2020).
At a microscopic level, the liver can be thought of as a collection of
niches that each play a part in metastatic progression. Although good
models exist for some of these niches, e.g. extravasation through
sinusoidal membranes, there remains scope for progress. How the liver
architecture determines the location and development of metastases
could be particularly informative here. For example, whether
polarisation of stromal cells and ECM along the centro-portal axis
affects cancer cell behaviour at different sites within the liver sinusoids
is currently unknown. Further, premetastatic changes to the liver may
disrupt sinusoid polarity, as has been shown to occur in liver fibrosis
(Gissen andArias, 2015). Application of multiplexed imaging of ECM
and cell markers during the early stages of metastasis in experimental
models can help provide in vivo support for the heterogeneity identified
in unbiased screens (Dobie et al., 2019).
Finally, there remains an unmet need for therapies specifically
targeting metastatic progression in order to address the main cause
of cancer-related mortality. Targeting the ECMmicroenvironment
is an attractive option given the broad influence it has on metastatic
progression. Although our understanding is incomplete, an
emerging conclusion from existing studies is that the key
signalling nodes related to ECM dynamics can dramatically alter
the course of metastasis in the liver. TGF-β (Costa-Silva et al.,
2015) and IL-6 (Lee et al., 2019) are key signalling molecules in
the premetastatic liver niche, and have shown promise in
preventing metastasis in preclinical models (Yang et al., 2002).
Unfortunately, early clinical trials with TGF-β inhibitors have not
been able to recapitulate the preclinical effect sizes, highlighting
both the complexity of human disease and the diversity of TGF-β
signalling (Teixeira et al., 2020). Other therapies targeting fibrosis
in established metastases could also have real clinical importance
(Hu et al., 2019), although their differential effects on primary
tumours need to be taken into account (Rhim et al., 2014). Ideally,
therapeutic targets should specifically disrupt the ECM dynamics
that support metastases without disrupting tissue homeostasis. The
recognition of ECM contributions from different cell types,
particularly cancer cells themselves, offers a promising new
approach here. These efforts will be able to integrate the diverse
methodologies with which to study the role of ECM dynamics in
liver metastasis that are now becoming available.
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